Please wait while the formulary information is being retrieved.
PROCRIT (EPOETIN ALFA)
- Anemia in chronic kidney disease
- Chemotherapy-induced anemia
- Anemia due to chemotherapy and radiotherapy combination
- Reduction of allogeneic blood transfusion in surgery
- Zidovudine-induced anemia
10,000 unit/mL injection solution
- Dosage information is not available
2,000 unit/mL injection solution
- Inject 100 unit/kg by subcutaneous route 3 times per week
20,000 unit/2 mL injection solution
- Inject 100 unit/kg by subcutaneous route 3 times per week
20,000 unit/mL injection solution
- Inject 100 unit/kg by subcutaneous route 3 times per week
3,000 unit/mL injection solution
- Inject 100 unit/kg by subcutaneous route 3 times per week
4,000 unit/mL injection solution
- Dosage information is not available
40,000 unit/mL injection solution
- Inject 100 unit/kg by subcutaneous route 3 times per week
10,000 unit/mL injection solution
- Dosage information is not available
2,000 unit/mL injection solution
- Inject 100 unit/kg by subcutaneous route 3 times per week
20,000 unit/2 mL injection solution
- Inject 100 unit/kg by subcutaneous route 3 times per week
20,000 unit/mL injection solution
- Inject 100 unit/kg by subcutaneous route 3 times per week
3,000 unit/mL injection solution
- Inject 100 unit/kg by subcutaneous route 3 times per week
4,000 unit/mL injection solution
- Dosage information is not available
40,000 unit/mL injection solution
- Inject 100 unit/kg by subcutaneous route 3 times per week
10,000 unit/mL injection solution
- Dosage information is not available
2,000 unit/mL injection solution
- Inject 100 unit/kg by subcutaneous route 3 times per week
20,000 unit/2 mL injection solution
- Inject 100 unit/kg by subcutaneous route 3 times per week
20,000 unit/mL injection solution
- Inject 100 unit/kg by subcutaneous route 3 times per week
3,000 unit/mL injection solution
- Inject 100 unit/kg by subcutaneous route 3 times per week
4,000 unit/mL injection solution
- Dosage information is not available
Anemia due to chemotherapy and radiotherapy combination
- Inject 150 unit/kg by subcutaneous route 3 times per week
- Inject 300 unit/kg by subcutaneous route 3 times per week
- Inject 150 unit/kg by intravenous route 3 times per week
- Inject 4 milliliters (40,000 unit) by subcutaneous route every 7 days
Anemia in chronic kidney disease
- Inject 50 unit/kg by subcutaneous route 3 times per week
- Inject 50 unit/kg by intravenous route 3 times per week
- Inject 100 unit/kg by subcutaneous route 3 times per week
- Inject 100 unit/kg by intravenous route 3 times per week
Chemotherapy-induced anemia
- Inject 150 unit/kg by subcutaneous route 3 times per week
- Inject 300 unit/kg by subcutaneous route 3 times per week
- Inject 150 unit/kg by intravenous route 3 times per week
- Inject 4 milliliters (40,000 unit) by subcutaneous route every 7 days
Zidovudine-induced anemia
- Inject 100 unit/kg by subcutaneous route 3 times per week
- Inject 100 unit/kg by intravenous route 3 times per week
- Inject 300 unit/kg by intravenous route 3 times per week
- Inject 300 unit/kg by subcutaneous route 3 times per week
- None
Contraindicated
- None
Severe
Moderate
- None
- Pure red cell aplasia
- Severe uncontrolled hypertension
Contraindicated
- Acute decompensated heart failure
- Acute myocardial infarction
- Cerebrovascular accident
- Coronary artery disease
- Deep venous thrombosis
- Pulmonary thromboembolism
- Thromboembolic disorder
- Vascular access thrombosis
Severe
Moderate
- Folate deficiency
- Hypertension
- Increased cardiovascular event risk
- Iron deficiency anemia
- Porphyria
- Seizure disorder
- Vitamin b12 deficiency
PROCRIT (EPOETIN ALFA)
- Anemia in chronic kidney disease
- Chemotherapy-induced anemia
- Anemia due to chemotherapy and radiotherapy combination
- Reduction of allogeneic blood transfusion in surgery
- Zidovudine-induced anemia
- Edema
- Fever
- Hypertension
- Tachycardia
- Vascular access thrombosis
- Arthralgias
- Diarrhea
- Fatigue
- General weakness
- Injection site sequelae
- Muscle spasm
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- Acute myocardial infarction
- Cerebrovascular accident
- Headache disorder
- Hypokalemia
- Pulmonary thromboembolism
- Seizure disorder
- Thrombotic disorder
- Transient cerebral ischemia
- Bone pain
- Depression
- Dizziness
- Dysphagia
- Hyperglycemia
- Myalgias
- Stomatitis
- Upper respiratory infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Chest pain
- Chronic heart failure
- Deep venous thrombosis
- Erythema multiforme
- Porphyria
- Pure red cell aplasia
- Shortened time to tumor progression
- Skin rash
- Stevens-johnson syndrome
- Thromboembolic disorder
- Toxic epidermal necrolysis
- Urticaria
Less Severe
- Chills
- Flu-like symptoms
- Hyperhidrosis
Contraindicated
Epoetin alfa (MDV)
Multidose vial contains benzyl alcohol: contraindicated in neonates and infants per manufacturer.
- 1 Day – 364 Days
- 1 Multidose vial contains benzyl alcohol: contraindicated in neonates and infants per manufacturer.
Severe Precaution
None
Management or Monitoring Precaution
None
Epoetin Alfa
- Severity Level:
2
- Additional Notes: Insuff human data avail; multiple dose vial contains ba and is ci
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Epoetin Alfa
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Discuss the risks and benefits of epoetin alfa with your doctor, as this medication may rarely cause very serious (possibly fatal) side effects, including blood clots, heart attack, stroke, or heart failure. It is very important to keep all lab appointments since your doctor will need to carefully check your red blood cell count and hemoglobin level. The lowest effective dose of this medication should be used.<br /><br /> When used to treat anemia related to cancer, this medication may also increase the risk of death and/or cause your tumor to grow faster. This medication should be stopped after completing a treatment course of chemotherapy as directed by your doctor.
| Anemia due to chemotherapy and radiotherapy combination | |
| D64.81 | Anemia due to antineoplastic chemotherapy |
| Z51.0 | Encounter for antineoplastic radiation therapy |
| Anemia in chronic kidney disease | |
| D63.1 | Anemia in chronic kidney disease |
| N18.4 | Chronic kidney disease, stage 4 (severe) |
| N18.5 | Chronic kidney disease, stage 5 |
| N18.6 | End stage renal disease |
| Z99.2 | Dependence on renal dialysis |
| Chemotherapy-induced anemia | |
| D64.81 | Anemia due to antineoplastic chemotherapy |
| Zidovudine-induced anemia | |
| D64.9 | Anemia, unspecified |
| 0-9 | A-Z |
|---|---|
| D63.1 | Anemia in chronic kidney disease |
| D64.81 | Anemia due to antineoplastic chemotherapy |
| D64.81 | Anemia due to antineoplastic chemotherapy |
| D64.9 | Anemia, unspecified |
| N18.4 | Chronic kidney disease, stage 4 (severe) |
| N18.5 | Chronic kidney disease, stage 5 |
| N18.6 | End stage renal disease |
| Z51.0 | Encounter for antineoplastic radiation therapy |
| Z99.2 | Dependence on renal dialysis |
Formulary Reference Tool